<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314819</url>
  </required_header>
  <id_info>
    <org_study_id>2013-013-00CH1</org_study_id>
    <nct_id>NCT02314819</nct_id>
  </id_info>
  <brief_title>A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)</brief_title>
  <acronym>FRESCO</acronym>
  <official_title>A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eighty-One Hospital of People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fruquintinib administered at 5mg once daily(QD) in 4 weeks treatment cycle (three weeks on&#xD;
      and one week off) was well tolerated and demonstrated encouraging preliminary clinical&#xD;
      antitumor activity in patients with metastatic colorectal cancer (CRC) in phase Ib and phase&#xD;
      2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in the&#xD;
      treatment of patients with metastatic CRC who have progressed after second line or above&#xD;
      standard chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial&#xD;
      to compare the efficacy and safety of Fruquintinib plus BSC versus placebo plus BSC in&#xD;
      patients with metastatic colorectal cancer who have progressed after second-line or above&#xD;
      standard chemotherapy. After checking eligibility criteria, subjects will be randomized into&#xD;
      Fruquintinib plus BSC group (treatment group) or placebo plus BSC group (control group) in a&#xD;
      ration of 2:1. Primary Efficacy Endpoint: Overall Survival (OS). Secondary Efficacy&#xD;
      Endpoints: Progression free survival (PFS) (According to RECIST Version 1.1), Objective&#xD;
      Response Rate (ORR), Disease Control Rate (DCR), . Safety and tolerance will be evaluated by&#xD;
      incidence, severity and outcomes of AEs and categorized by severity in accordance with the&#xD;
      NCI CTC AE Version 4.0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">January 17, 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>from randomization until death due to any cause, assessed up to 2 year</time_frame>
    <description>every two months after end of treatment (EOT) observation period at 30 days after the last medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year</time_frame>
    <description>Tumor assessment will be performed using radiography method every 8 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year</time_frame>
    <description>Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year</time_frame>
    <description>Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance evaluated by incidence, severity and outcomes of AEs</measure>
    <time_frame>from first dose to within 30 days after the last dose</time_frame>
    <description>Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">416</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fruquintinib</intervention_name>
    <description>fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off</description>
    <arm_group_label>treatment arm</arm_group_label>
    <other_name>HMPL-013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off</description>
    <arm_group_label>control arm</arm_group_label>
    <other_name>HMPL-013 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 and ≤ 75 years of age , with ≥ 40Kg&#xD;
&#xD;
          -  Histological or cytological confirmed colorectal cancer&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  Standard regimen failed or no standard regimen available&#xD;
&#xD;
          -  Adequate hepatic, renal, heart, and hematologic functions&#xD;
&#xD;
          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)&#xD;
&#xD;
          -  Signed and dated informed consent&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pregnant or lactating women&#xD;
&#xD;
          -  Any factors that influence the usage of oral administration&#xD;
&#xD;
          -  Evidence of CNS metastasis&#xD;
&#xD;
          -  Intercurrence with one of the following: non-controlled hypertension, coronary artery&#xD;
             disease, arrhythmia and heart failure&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR&#xD;
             inhibition&#xD;
&#xD;
          -  Disability of serious uncontrolled intercurrence infection&#xD;
&#xD;
          -  Proteinuria ≥ 2+ (1.0g/24hr)&#xD;
&#xD;
          -  Have evidence or a history of bleeding tendency within two months of the enrollment,&#xD;
             regardless of seriousness&#xD;
&#xD;
          -  Within 12 months before the first treatment occurs artery/venous thromboembolic&#xD;
             events, such as cerebral vascular accident (including transient ischemic attack) etc.&#xD;
&#xD;
          -  Within 6 months before the first treatment occurs acute myocardial infarction, acute&#xD;
             coronary syndrome or CABG&#xD;
&#xD;
          -  Bone fracture or wounds that was not cured for a long time&#xD;
&#xD;
          -  Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi pharma Investigational Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma investigational site</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <zip>545005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchison Medi Pharma Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Fan S, Hua Y, Su W. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018 Jun 26;319(24):2486-2496. doi: 10.1001/jama.2018.7855.</citation>
    <PMID>29946728</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

